Vogt-Koyanagi-Harada (VKH) syndrome is a rare autoimmune condition that primarily affects pigmented tissues in the body, especially the eyes, ears, skin, and central nervous system. It is characterized by inflammation that targets melanocytes, leading to a wide range of visual and systemic symptoms. VKH syndrome often begins suddenly and can significantly affect a patient’s quality of life if not diagnosed and treated promptly.

The condition typically progresses through multiple stages. The initial phase may involve flu-like symptoms, headaches, and neck stiffness, followed by visual disturbances such as blurred vision, light sensitivity, and eye pain. As the disease advances, inflammation in the eyes can lead to uveitis, retinal detachment, and reduced visual acuity. Some individuals also experience hearing issues, tinnitus, or changes in skin pigmentation.

Early diagnosis plays a crucial role in managing VKH syndrome effectively. Ophthalmic examinations, imaging techniques, and careful clinical assessment are essential to differentiate VKH from other inflammatory eye diseases. Since the condition can mimic other disorders, awareness among healthcare providers is key to preventing delays in treatment.

Treatment strategies primarily focus on controlling inflammation and preventing long-term complications. Corticosteroids are commonly used during the acute phase to suppress immune activity. In more severe or recurring cases, immunosuppressive therapies may be introduced to maintain disease control and reduce steroid dependence.